Telehealth Aerobic Exercise & Cognitive Training for Schizophrenia
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of this treatment for schizophrenia?
Research shows that combining aerobic exercise with cognitive training can improve thinking skills and daily functioning in people with schizophrenia. Aerobic exercise may enhance brain function by increasing a protein that helps with learning, and when paired with cognitive training, it can lead to better cognitive flexibility and processing speed.12345
Is the combination of aerobic exercise and cognitive training safe for people with schizophrenia?
How does the Telehealth Aerobic Exercise & Cognitive Training treatment for schizophrenia differ from other treatments?
This treatment is unique because it combines aerobic exercise with cognitive training, which together enhance brain function and cognitive abilities more effectively than cognitive training alone. Aerobic exercise increases brain-derived neurotrophic factor (BDNF), promoting brain plasticity and improving learning capacity, which is further enhanced by cognitive training.134810
What is the purpose of this trial?
The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other half will be randomly assigned to the Healthy Living Group condition. The primary outcome measures are improvement in cognition and level of engagement in the in-group and at-home exercise sessions. Increases in the level of the patient's serum brain-derived neurotropic factor (specifically Mature BDNF) which causes greater brain neuroplasticity and is indicator of engagement in aerobic exercise, will be measured early in the treatment phase in order to confirm engagement of this target. In order to demonstrate the feasibility and portability of this intervention outside of academic research programs, the interventions will be provided via videoconferencing. The proposed study will incorporate additional methods to maximize participation in the exercise condition, including the use of the Moderated Online Social Therapy (MOST) platform to enhance motivation for treatment based on Self-Determination Theory principles, and a "bridging" group to help the participants generalize gains to everyday functioning. In addition, the exercise group participants will receive personally tailored text reminders to exercise.
Research Team
Keith H Nuechterlein, PhD
Principal Investigator
University of California, Los Angeles
Eligibility Criteria
This trial is for individuals aged 18-45 who have experienced their first psychotic episode within the last two years and are diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder. Participants should be fluent in English, live near UCLA's Aftercare Research Program, and be able to commute there.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cognitive training and are randomly assigned to either the aerobic exercise and strength training condition or the Healthy Living Group condition. The interventions are delivered via videoconferencing.
Follow-up
Participants are monitored for changes in cognitive performance and engagement in exercise sessions.
Extension
Participants continue with reduced frequency of group sessions to maintain exercise and cognitive training benefits.
Treatment Details
Interventions
- Aerobic Exercise Program
- Chorus Participatory Text Messaging Program
- Cognitive training
- Healthy Living Group (HLG)
- Moderated Online Social Therapy (MOST)
Aerobic Exercise Program is already approved in European Union, United States for the following indications:
- Improvement in cognitive functioning in schizophrenia
- Reduction in psychiatric symptoms of schizophrenia
- Enhancement of global functioning and quality of life
- Improvement in cognitive functioning in schizophrenia
- Reduction in psychiatric symptoms of schizophrenia
- Enhancement of global functioning and quality of life
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator